174 related articles for article (PubMed ID: 31488436)
41. A novel jaspine B-ceramide hybrid modulates sphingolipid metabolism.
Garcia V; Le Faouder P; Dupuy A; Levade T; Ballereau S; Génisson Y
Chem Biodivers; 2015 Jul; 12(7):1115-25. PubMed ID: 26172331
[TBL] [Abstract][Full Text] [Related]
42. Novel agents targeting bioactive sphingolipids for the treatment of cancer.
Adan-Gokbulut A; Kartal-Yandim M; Iskender G; Baran Y
Curr Med Chem; 2013; 20(1):108-22. PubMed ID: 23244584
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
Noble CO; Krauze MT; Drummond DC; Forsayeth J; Hayes ME; Beyer J; Hadaczek P; Berger MS; Kirpotin DB; Bankiewicz KS; Park JW
Nanomedicine (Lond); 2014 Jul; 9(14):2099-108. PubMed ID: 24494810
[TBL] [Abstract][Full Text] [Related]
44. Potential therapeutic targets for atherosclerosis in sphingolipid metabolism.
Yu Z; Peng Q; Huang Y
Clin Sci (Lond); 2019 Mar; 133(6):763-776. PubMed ID: 30890654
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.
Myhren L; Nilssen IM; Nicolas V; Døskeland SO; Barratt G; Herfindal L
Eur J Pharm Biopharm; 2014 Sep; 88(1):186-93. PubMed ID: 24747809
[TBL] [Abstract][Full Text] [Related]
46. Sphingolipids in apoptosis.
Tirodkar TS; Voelkel-Johnson C
Exp Oncol; 2012 Oct; 34(3):231-42. PubMed ID: 23070008
[TBL] [Abstract][Full Text] [Related]
47. The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas.
Eikesdal HP; Landuyt W; Dahl O
Cancer Lett; 2002 Apr; 178(2):209-17. PubMed ID: 11867206
[TBL] [Abstract][Full Text] [Related]
48. Bioactive sphingolipids in response to chemotherapy: a scope on leukemias.
Ekiz HA; Baran Y
Anticancer Agents Med Chem; 2011 May; 11(4):385-97. PubMed ID: 21453240
[TBL] [Abstract][Full Text] [Related]
49. Sphingolipids in mitochondria.
Hernández-Corbacho MJ; Salama MF; Canals D; Senkal CE; Obeid LM
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Jan; 1862(1):56-68. PubMed ID: 27697478
[TBL] [Abstract][Full Text] [Related]
50. [Progress on targeted therapy of acute myeloid leukemia with active components of Chinese herbal medicines].
Zhen T; Chen SJ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Jan; 29(1):14-8. PubMed ID: 19338145
[No Abstract] [Full Text] [Related]
51. Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents.
Giles C; Takechi R; Mellett NA; Meikle PJ; Dhaliwal S; Mamo JC
J Neurochem; 2017 May; 141(3):413-422. PubMed ID: 28129448
[TBL] [Abstract][Full Text] [Related]
52. The sphingolipid salvage pathway in ceramide metabolism and signaling.
Kitatani K; Idkowiak-Baldys J; Hannun YA
Cell Signal; 2008 Jun; 20(6):1010-8. PubMed ID: 18191382
[TBL] [Abstract][Full Text] [Related]
53. The effect of altered sphingolipid acyl chain length on various disease models.
Park WJ; Park JW
Biol Chem; 2015 Jun; 396(6-7):693-705. PubMed ID: 25720066
[TBL] [Abstract][Full Text] [Related]
54. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
55. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.
Prinetti A; Millimaggi D; D'Ascenzo S; Clarkson M; Bettiga A; Chigorno V; Sonnino S; Pavan A; Dolo V
Biochem J; 2006 Apr; 395(2):311-8. PubMed ID: 16356169
[TBL] [Abstract][Full Text] [Related]
56. Vinorelbine--a clinical review.
Gregory RK; Smith IE
Br J Cancer; 2000 Jun; 82(12):1907-13. PubMed ID: 10864196
[No Abstract] [Full Text] [Related]
57. Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models.
Carvalho VFM; Migotto A; Giacone DV; de Lemos DP; Zanoni TB; Maria-Engler SS; Costa-Lotufo LV; Lopes LB
Eur J Pharm Sci; 2017 Nov; 109():131-143. PubMed ID: 28735040
[TBL] [Abstract][Full Text] [Related]
58. Antitumor activity of a novel and orally available inhibitor of serine palmitoyltransferase.
Yaguchi M; Shibata S; Satomi Y; Hirayama M; Adachi R; Asano Y; Kojima T; Hirata Y; Mizutani A; Kiba A; Sagiya Y
Biochem Biophys Res Commun; 2017 Mar; 484(3):493-500. PubMed ID: 28108287
[TBL] [Abstract][Full Text] [Related]
59. Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease.
Lim KG; Gray AI; Anthony NG; Mackay SP; Pyne S; Pyne NJ
Arch Toxicol; 2014 Dec; 88(12):2213-32. PubMed ID: 25344023
[TBL] [Abstract][Full Text] [Related]
60. [Ceramide-centered sphingolipid metabolism].
Kitatani K; Asano S; Hashimoto M; Taniguchi M; Okazaki T
Seikagaku; 2011 Jun; 83(6):495-505. PubMed ID: 21800680
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
